1 / 7

K.H. Buchheit, A. Daas, C.M. Nübling, J.M. Spieser 3 July 2003

Collaborative Study for Establishment of a Ph. Eur. BRP for B19 Virus DNA Testing of Plasma Pools by NAT. K.H. Buchheit, A. Daas, C.M. Nübling, J.M. Spieser 3 July 2003. SoGAT XVI. Candidate BRP. B19 positive plasma (ca 10 9 IU/ml), from window phase Liquid bulk material (10 6 IU/ml)

kendra
Télécharger la présentation

K.H. Buchheit, A. Daas, C.M. Nübling, J.M. Spieser 3 July 2003

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Collaborative Study for Establishment of a Ph. Eur. BRP for B19 Virus DNA Testing of Plasma Pools by NAT K.H. Buchheit, A. Daas, C.M. Nübling, J.M. Spieser 3 July 2003 SoGAT XVI

  2. Candidate BRP B19 positive plasma (ca 109 IU/ml), from window phase Liquid bulk material (106 IU/ml) • Diluent: Human plasma negative for HCV, HBV, HIV1 (NAT & serology) Lyophilisation: • ca 5400 vials, 0.5 ml • residual water: 0.98 ± 0.65% K.H. Buchheit SoGAT 3/7/03

  3. Collaborative study • 16 labs (OMCLs, manuf., NAT test labs, kit manuf.) • Calibration vs 1st IS (500 000 IU/vial) • B19 negative plasma as dilution matrix • Qualitative assay (13 labs) • 4 independent tests • dilution series proposed • ≥ 3 half-log dil. around dilutional end point • Quantitative assay (5 labs) • Measure in parallel, diff. conc., linear range K.H. Buchheit SoGAT 3/7/03

  4. Results (1)(Values as log10 IU/ml) • Qualitative assay (n = 12) 5.64 ± 0.17 (C.L.: 67 - 150%) • Quantitative assay (n = 5) 5.83 ± 0.05 (C.L.: 88 - 113%) • Combined 5.80 ± 0.05 (C.L.: 86 - 117%) 630 957 IU/ml K.H. Buchheit SoGAT 3/7/03

  5. Results (2) Grey cells: qualitative assays Black cells: quantitative assays K.H. Buchheit SoGAT 3/7/03

  6. cBRP suitable for intended purpose • Assigned potency: 105.8 IU/ml • Dilution for threshold control: 1/101.8 = 1/63 No. positive results/ no. assays for each dilution K.H. Buchheit SoGAT 3/7/03

  7. Next Steps • OMCL guideline for B19 NAT validation (M. Nübling) • Validation panel • PTS studies for OMCLs & manufactures (if requested) K.H. Buchheit SoGAT 3/7/03

More Related